Application No.: 09/982,892

Amendment Dated 29 December 2003

Response to Office Action of 27 June 2003

REMARKS

Claims 1-18 are pending in the instant application.

Claims 14 to 17 have been amended to more clearly define the organocobalt complex.

Support for these amendments can be found at page 12, line 8 - page 13, line 23. It is submitted that

none of these amendments constitute new matter, and their entry is requested.

Rejection under 35 U.S.C. §112, first paragraph

On pages 2 and 3, the Office rejects claims 1-18 under 35 USC §112, first paragraph for lack

of a written description. In particular, the Office alleges that the disclosure does not indicate what

distinguishing attributes are shared by the members of the genera comprising covalently conjugated

cobalt atoms and bioactive molecules in organocobalt complexes. On page 3, the Office also alleges

that the specification fails to teach or adequately describe a representative number of species. The

Office concludes that the inventors were not in possession of the claimed genera.

Applicants respectfully submits that the person skilled in the art would have, from the

examples provided, recognized that the inventors were in possession of the claimed genera. The

present application discloses a representative number of species of bioactive agents on pages 10 and

11 of the specification, in particular on page 10, lines 26-30 and page 11, lines 16-25. See also, page

3, lines 5 to page 4, line 12 in conjunction with page 1, lines 21-24 as well as page 52, lines 3-14.

Here, the specification provides examples of peptides and nucleic acids that can be used as bioactive

agents in the context of the present invention either directly or by incorporation of reference. The

person skilled in the art would understand that the particular bioactive agent used is a function of the

disease to be targeted. The present application also discloses a representative number of

organocobalt complexes on pages 12 and 13 of the specification. Covalent attachment of a bioactive

agent to a cobalt atom is taught on pages 14 and 19-43 of the disclosure, in particular pages 35-38.

From the disclosure, the person skilled in the art would be readily able to recognize how to attach

any of the bioactive agents of the claimed genus.

Page 6 of 8

Application No.: 09/982,892

Amendment Dated 29 December 2003

Response to Office Action of 27 June 2003

Applicants have amended claims 14 to 17 to more clearly define the organocobalt complex

as supported at pages 12-13 of the specification.

In view of the above amendments and remarks, it is submitted that the claimed invention is

fully described by the specification. Withdrawal of this rejection is requested.

Double Patenting

On pages 3 and 4, the Office rejects claims 1-18 under the judicially created doctrine of

obviousness-type double patenting over claims 1-28 of the parent application, now U.S. Patent No.

6,315,978.

A terminal disclaimer, disclaiming the patent term of any patent that might issue for the

present application that would extend the term of such a patent beyond the term of commonly owned

U.S. Patent No. 6,315,978, is attached hereto.

The submission of this terminal disclaimer obviates this rejection. Withdrawal of this

rejection is requested.

Claim Amendments

Any amendments to the claims were made solely for the purpose of clarifying the respective

claim. In no case should such an amendment of an element of a claim be construed as a surrender

of equivalents.

In view of the above amendments and remarks, in conjunction with the remarks made in the

previous amendment, it is believed that the claims satisfy the requirements of the patent statutes and

are patentable over the prior art. Reconsideration of the instant application and early notice of

Page 7 of 8

Application No.: 09/982,892

Amendment Dated 29 December 2003 Response to Office Action of 27 June 2003

allowance are requested. The Examiner is invited to telephone the undersigned if it is deemed to expedite allowance of the application.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

By

Voyce von Natzmer
Registration No. 48,120
Attorney for Applicant

1425 K Street, N.W., Suite 800

Washington, D.C. 20005 phone: 202-783-6040

fax: 202-783-6031

L:\2317\PTOPAPER\105A.amend1.wpd